	The Company recognized stock-based compensation expense within selling, general and administrative expense as follows
(in thousands):
				Fiscal Year Ended August 31,
				2017		2016		2015
		Restricted stock and stock appreciation rights ("SARS")		$	42,122	$	52,459	$	58,033
		Employee stock purchase plan			6,334		6,538		4,717
		Other			88		―		(187)
			Total	$	48,544	$	58,997	$	62,563

Equity Compensation Plan

The 2011 Stock Award and Incentive Plan (the “2011 Plan”) provides for the grant of restricted stock awards, restricted stock unit awards and other stock-based awards.

Upon adoption of the 2011 Plan, the 2002 Stock Incentive Plan (the “2002 Plan”) was terminated. For any outstanding awards granted under the 2002 Plan that expire, are canceled or forfeited after the termination of the 2002 Plan, the shares are available for issuance under the 2011 Plan. Following is a reconciliation of the shares available to be issued under the 2011 Plan as of August 31, 2017:


		Shares Available for Grant
Balance as of August 31, 2016		4,898,739
	Shares authorized ⁽¹⁾	4,950,000
	SARS canceled	1,357,386
	Restricted stock awards forfeited, net of grants⁽²⁾	1,022,811
Balance as of August 31, 2017		12,228,936

⁽¹⁾	In January 2017, the Company’s stockholders approved increasing the maximum aggregate number of shares available for
	issuance under the 2011 Plan to 23,300,000.
⁽²⁾	Represents the maximum number of shares that can be issued based on the achievement of certain performance criteria.

							Weighted-
					Weighted-		Average
			Average		Average		Remaining
		SARS	Intrinsic Value		Exercise		Contractual
		Outstanding	(in thousands)		Price		Life (years)
Outstanding as of August 31, 2016		2,439,066	$	1,066	$	25.32	1.13
	SARS canceled	(1,357,386)			$	29.15
	SARS exercised	(762,439)			$	20.78
Outstanding and exercisable as of August 31, 2017		319,241	$	3,651	$	19.91	2.10

Restricted Stock Awards

Certain key employees have been granted time-based, performance-based and market-based restricted stock unit awards. The time-based restricted stock units granted generally vest on a graded vesting schedule over three years. The performance-based restricted stock units generally vest on a cliff vesting schedule over three to five years and provide a range of vesting possibilities of up to a maximum of 100% or 150%, depending on the specified performance condition and the level of achievement obtained. The market-based restricted stock units have a vesting condition that is tied to the Company’s stock performance in relation to the Standard and Poor’s (S&P) Super Composite Technology Hardware and Equipment Index.

	The following table summarizes restricted stock activity from August 31, 2016 through August 31, 2017:


					Weighted-
					Average
					Grant-Date
				Shares	Fair Value
		Outstanding as of August 31, 2016		14,777,178	$	21.09
		Changes during the period
			Shares granted⁽¹⁾	3,507,690	$	23.65
			Shares vested	(2,102,049)	$	20.94
			Shares forfeited	(4,530,500)	$	20.84
		Outstanding as of August 31, 2017		11,652,319	$	22.00

⁽¹⁾	For those shares granted that are based on the achievement of certain performance criteria, the amount represents the maximum number of shares that can vest. During the fiscal year ended August 31, 2017, the Company awarded approximately 1.8 million time-based restricted stock units, 0.6 million performance-based restricted stock units and 0.4 million market-based restricted stock units based on target performance criteria.

	Following represents the restricted stock and SARS stock-based compensation information for the periods indicated (in thousands):

			Fiscal Year Ended August 31,
			2017			2016		2015
		Intrinsic value of SARS exercised	$	5,053		$	506	$	954
		Fair value of SARS vested	$	―		$	―	$	2,754
		Fair value of restricted stock vested	$	44,010		$	34,857	$	33,413
		Tax benefit (expense) for stock compensation expense⁽¹⁾	$	560		$	991	$	(351)
		Capitalized stock compensation expense⁽²⁾	$	313		$	387	$	387
		Unrecognized stock-based compensation expense - restricted stock	$	45,158
		Remaining weighted-average period for restricted stock expense		1.4	years

⁽¹⁾	Classified as income tax expense within the Consolidated Statements of Operations.
⁽²⁾	Classified as inventories within the Consolidated Balance Sheets.

Employee Stock Purchase Plan

In January 2017, the Company’s shareholders approved to increase the shares available for issuance under the 2011 Employee Stock Purchase Plan (the “ESPP”) to 12,000,000.

Employees are eligible to participate in the ESPP after 90 days of employment with the Company. The ESPP permits eligible employees to purchase common stock through payroll deductions, which may not exceed 10% of an employee’s compensation, as defined in the ESPP, at a price equal to 85% of the fair value of the common stock at the beginning or end of the offering period, whichever is lower. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code. As of August 31, 2017, 5,784,461 shares remained available for issue under the 2011 ESPP.

	The fair value of shares issued under the ESPP was estimated on the commencement date of each offering period using the
Black-Scholes option pricing model. The following weighted-average assumptions were used in the model for each respective period:

			Fiscal Year Ended August 31,
			2017		2016		2015
		Expected dividend yield	0.8	%	0.7	%	0.8	%
		Risk-free interest rate	0.5	%	0.3	%	0.1	%
		Expected volatility ⁽¹⁾	33.0	%	28.1	%	24.5	%
		Expected life	0.5 years		0.5 years		0.5 years

⁽¹⁾	The expected volatility was estimated using the historical volatility derived from the Company's common stock.

Dividends

The following table sets forth certain information relating to the Company’s cash dividends declared to common stockholders during fiscal years 2017 and 2016:

				Total of Cash
	Dividend	Dividend		Dividends		Date of Record for	Dividend Cash
	Declaration Date	per Share		Declared		Dividend Payment	Payment Date
	(in thousands, except for per share data)
Fiscal year 2017:	October 20, 2016	$	0.08	$	15,248	November 15, 2016	December 1, 2016
	January 26, 2017	$	0.08	$	15,051	February 15, 2017	March 1, 2017
	April 20, 2017	$	0.08	$	14,840	May 15, 2017	June 1, 2017
	July 20, 2017	$	0.08	$	14,698	August 15, 2017	September 1, 2017

Fiscal year 2016:	October 14, 2015	$	0.08	$	15,906	November 16, 2015	December 1, 2015
	January 21, 2016	$	0.08	$	15,947	February 16, 2016	March 1, 2016
	April 21, 2016	$	0.08	$	15,940	May 16, 2016	June 1, 2016
	July 21, 2016	$	0.08	$	15,575	August 15, 2016	September 1, 2016

Share Repurchases

In June 2016, the Company’s Board of Directors (the “Board”) authorized the repurchase of up to $400.0 million of the Company’s common stock (the “2016 Share Repurchase Program”). As of August 31, 2017, $400.0 million of shares had been repurchased under the 2016 Share Repurchase Program, which utilized the total amount authorized by the Board.

In July 2017, the Board authorized the repurchase of up to $450.0 million of the Company’s common stock (the “2017 Share Repurchase Program”). The 2017 Share Repurchase Program expires on August 31, 2018. As of August 31, 2017, $449.9 million remains available under the 2017 Share Repurchase Program.